$VTAE on close watch, Vitae Pharmaceuticals (VT
Post# of 22755
Posted On: 03/27/2016 11:03:11 PM
$VTAE on close watch,
Vitae Pharmaceuticals (VTAE) Short Interest Disclosure
By David Thorn -
March 28, 2016
Vitae Pharmaceuticals (NASDAQ:VTAE), A increase of 251,729 shares or 14.5% was observed in the short interest of Vitae Pharmaceuticals, Inc. The interest on March 15,2016 came in at 1,982,613 shares and as per the average daily trading of 1,218,235 shares, the days to cover are 2. The increased interest is 13.2% of the floated shares. The data of February 29,2016 put the interest at 1,730,884 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on March 24th.
Vitae Pharmaceuticals (NASDAQ:VTAE) witnessed a decline in the market cap on Thursday as its shares dropped 10.85% or 0.73 points. After the session commenced at $6.5, the stock reached the higher end at $6.79 while it hit a low of $5.84. With the volume soaring to 4,767,088 shares, the last trade was called at $6. The company has a 52-week high of $18.71. The company has a market cap of $132 million and there are 22,079,610 shares in outstanding. The 52-week low of the share price is $4.08.
Currently the company Insiders own 20.1% of Vitae Pharmaceuticals shares according to the proxy statements. Institutional Investors own 71.04% of Vitae Pharmaceuticals shares. Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange,The director of Vitae Pharmaceuticals, Inc, Hayden Donald J Jr sold 16,130 shares at $18 on December 29, 2015. The Insider selling transaction had a total value worth of $290,340. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Vitae Pharmaceuticals, Inc. has lost 11.63% in the last five trading days and dropped 36.64% in the last 4 weeks. Vitae Pharmaceuticals, Inc. has dropped 62.31% during the last 3-month period . Year-to-Date the stock performance stands at -66.85%. Vitae Pharmaceuticals (NASDAQ:VTAE) witnessed a decline in the market cap on Thursday as its shares dropped 10.85% or 0.73 points. After the session commenced at $6.5, the stock reached the higher end at $6.79 while it hit a low of $5.84. With the volume soaring to 4,767,088 shares, the last trade was called at $6. The company has a 52-week high of $18.71. The company has a market cap of $132 million and there are 22,079,610 shares in outstanding. The 52-week low of the share price is $4.08.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.
Vitae Pharmaceuticals (VTAE) Short Interest Disclosure
By David Thorn -
March 28, 2016
Vitae Pharmaceuticals (NASDAQ:VTAE), A increase of 251,729 shares or 14.5% was observed in the short interest of Vitae Pharmaceuticals, Inc. The interest on March 15,2016 came in at 1,982,613 shares and as per the average daily trading of 1,218,235 shares, the days to cover are 2. The increased interest is 13.2% of the floated shares. The data of February 29,2016 put the interest at 1,730,884 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on March 24th.
Vitae Pharmaceuticals (NASDAQ:VTAE) witnessed a decline in the market cap on Thursday as its shares dropped 10.85% or 0.73 points. After the session commenced at $6.5, the stock reached the higher end at $6.79 while it hit a low of $5.84. With the volume soaring to 4,767,088 shares, the last trade was called at $6. The company has a 52-week high of $18.71. The company has a market cap of $132 million and there are 22,079,610 shares in outstanding. The 52-week low of the share price is $4.08.
Currently the company Insiders own 20.1% of Vitae Pharmaceuticals shares according to the proxy statements. Institutional Investors own 71.04% of Vitae Pharmaceuticals shares. Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange,The director of Vitae Pharmaceuticals, Inc, Hayden Donald J Jr sold 16,130 shares at $18 on December 29, 2015. The Insider selling transaction had a total value worth of $290,340. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Vitae Pharmaceuticals, Inc. has lost 11.63% in the last five trading days and dropped 36.64% in the last 4 weeks. Vitae Pharmaceuticals, Inc. has dropped 62.31% during the last 3-month period . Year-to-Date the stock performance stands at -66.85%. Vitae Pharmaceuticals (NASDAQ:VTAE) witnessed a decline in the market cap on Thursday as its shares dropped 10.85% or 0.73 points. After the session commenced at $6.5, the stock reached the higher end at $6.79 while it hit a low of $5.84. With the volume soaring to 4,767,088 shares, the last trade was called at $6. The company has a 52-week high of $18.71. The company has a market cap of $132 million and there are 22,079,610 shares in outstanding. The 52-week low of the share price is $4.08.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼